Headlines about Genomic Health (NASDAQ:GHDX) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genomic Health earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.4219535946429 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s analysis:

Several research analysts have recently weighed in on GHDX shares. Canaccord Genuity reiterated a “buy” rating and set a $39.00 price target on shares of Genomic Health in a research note on Wednesday, November 15th. ValuEngine cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Jefferies Group reiterated a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research note on Friday, October 20th. Zacks Investment Research upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. Finally, Cowen reiterated a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $32.67.

Shares of Genomic Health (NASDAQ GHDX) opened at $30.05 on Wednesday. Genomic Health has a 52-week low of $26.37 and a 52-week high of $34.02.

In other Genomic Health news, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $31.00, for a total transaction of $155,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 16,379 shares of company stock worth $516,831 over the last 90 days. Insiders own 46.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/12/12/genomic-health-ghdx-earning-somewhat-favorable-news-coverage-accern-reports.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.